HOME >> BIOLOGY >> NEWS
Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis

DALLAS Sept. 26, 2003 Researchers at UT Southwestern Medical Center at Dallas have tested and validated novel proteins, created by California-based Xencor, that block activity of a major molecule involved in the onset of inflammation, an innovation that may translate into new therapeutic options for people with rheumatoid arthritis.

Researchers at both institutions report in today's issue of Science that blocking the activation of a regulator of inflammation called tumor necrosis factor (TNF) decreased swelling by 25 percent in a rodent model of the human disease rheumatoid arthritis. Elevated TNF levels are associated with the onset of rheumatoid arthritis.

The uniqueness of the new inhibitors, the scientific team reports, lies in their design and mode of action. Unlike the drugs that are currently available, the structure and sequence of these newly designed molecules are similar to naturally produced proteins, making it less likely that the body will elicit an immune response to fight off foreign agents.

"What we've engineered are variant proteins that are very similar to the protein that the body expresses on its own, which makes it less likely that the body will see it as foreign," said Dr. Mal Tansey, a lead author of the study and assistant professor of physiology at UT Southwestern, where some of the in vivo testing and validation was completed and where work will continue on these TNF inhibitors.

"The inhibitors are actually modified versions of the TNF protein that is naturally found in the body, but with a few mutations that prevent them from binding to receptors but still allow the proteins to bind TNF. The end result is sequestration of active TNF away from the receptors that mediate inflammatory responses implicated in rheumatoid arthritis and several other autoimmune diseases," said Dr. Tansey, former member of the Xencor team.

These findings provide a "promising new avenue" for physicians who treat the 2.
'"/>

Contact: Amy Shields
amy.shields@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
25-Sep-2003


Page: 1 2 3

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2019)... ... May 30, 2019 , ... Enso Discoveries Chief Executive Officer, Patrick Farley, is ... as a way to express his gratitude and respect for those who have served ... Enso Discoveries — presented a check for $1,000 to the Green Beret ...
(Date:5/24/2019)... (PRWEB) , ... May 24, 2019 , ... The newest ... and is now available on the company’s global website. , Crystallography Times is a ... crystal X-ray diffraction. It serves the X-ray analysis community by presenting the latest news ...
(Date:5/23/2019)... SAN FRANCISCO (PRWEB) , ... May 23, 2019 ... ... Intelligent Virtual Agents for sales and service organizations, today announced its ... report identifies Inference Solutions as the intelligent virtual agent (IVA) market share leader, ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 10, 2019 , ... Advancements with Ted ... episode, scheduled to broadcast 4Q/2019. Check your local listings for more information. , ... about how its technology facilitates laboratories to improve efficiency and quality of research ...
(Date:6/11/2019)... (PRWEB) , ... June 11, 2019 , ... ... of Personalized Stem Cells Inc. (PSC) , has announced that their GMP ... Health, Food and Drug Branch for manufacturing. This is an important milestone ...
(Date:5/31/2019)... ... 2019 , ... For many years, the primary forms of cancer treatment have ... Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR ... receptors known as “CARs”. The CAR enables the final product to produce chemicals in ...
(Date:5/31/2019)... , ... May 30, 2019 , ... ... is pleased to announce the strategic acquisition of Metabiologics, Inc., a globally recognized ... provides Object exclusive ownership and commercialization rights to a full spectrum of botulinum ...
Breaking Biology Technology:
Cached News: